| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fe70490047125a7f0ada8d0785c405d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-14144
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2019-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9389fe33a72ca0c5f188a4c08d5daed8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bce37af706ae45d38533f54cac09333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f033b936a7596aef22eadcb5147cfa |
| publicationDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021050094-A1 |
| titleOfInvention |
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| abstract |
Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO. 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022232790-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023158990-A1 |
| priorityDate |
2019-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |